Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
| | | |

Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…

NIH funding cuts have impacted more than 74,000 people enrolled in trials
| | | | | | | | | | | | | | | | | |

NIH funding cuts have impacted more than 74,000 people enrolled in trials

On Nov. 17, 2025, a JAMA published study found that more than 74,000 people have had their lives…